ZA88577B - Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis - Google Patents

Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis

Info

Publication number
ZA88577B
ZA88577B ZA880577A ZA88577A ZA88577B ZA 88577 B ZA88577 B ZA 88577B ZA 880577 A ZA880577 A ZA 880577A ZA 88577 A ZA88577 A ZA 88577A ZA 88577 B ZA88577 B ZA 88577B
Authority
ZA
South Africa
Prior art keywords
hyperlipidaemia
atherosclerosis
treatment
pyridoxine
prevention
Prior art date
Application number
ZA880577A
Inventor
Ulrich Speck Dr.
Original Assignee
Ulrich Speck Dr.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulrich Speck Dr. filed Critical Ulrich Speck Dr.
Publication of ZA88577B publication Critical patent/ZA88577B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Pyridoxine derivatives and their salts, in particular pyridoxal, pyridoxal phosphate, pyridoxamine and pyridoxamine phosphate, are used in the prophylaxis and treatment of hyperlipidaemia and atherosclerosis. Exceptions are pyridoxine-5'-phosphoric acid glutamate and aspartate, which are described in DE 2,461,742 C2. Natural, highly compatible, chemically unambiguously described and adequately stable substances having good activity for long term treatments are thereby made available. The buccal administration form and enteric-resistant forms have proved particularly suitable.
ZA880577A 1987-02-18 1988-01-28 Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis ZA88577B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873705549 DE3705549A1 (en) 1987-02-18 1987-02-18 USE OF PYRIDOXINE DERIVATIVES IN THE PROPHYLAXIS AND THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS

Publications (1)

Publication Number Publication Date
ZA88577B true ZA88577B (en) 1988-07-28

Family

ID=6321453

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA880577A ZA88577B (en) 1987-02-18 1988-01-28 Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis

Country Status (12)

Country Link
EP (1) EP0282696B1 (en)
JP (2) JPH0710777B2 (en)
KR (1) KR950009094B1 (en)
AT (1) ATE82125T1 (en)
CA (1) CA1340246C (en)
DE (2) DE3705549A1 (en)
DK (1) DK55888A (en)
EG (1) EG18335A (en)
ES (1) ES2052609T3 (en)
GR (1) GR3006693T3 (en)
HU (1) HUT47850A (en)
ZA (1) ZA88577B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6740668B1 (en) 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6750209B1 (en) 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6730686B1 (en) 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
WO2000022094A2 (en) * 1998-10-09 2000-04-20 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
CA2366602A1 (en) 1999-03-08 2000-09-14 Medicure Inc. Pyridoxal analogues for vitamin b-6 disorders
WO2001003682A2 (en) 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
EP1210117A2 (en) 1999-08-24 2002-06-05 Medicure International Inc. Compositons for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
PT1268498E (en) 2000-02-29 2005-07-29 Medicure Int Inc CARDIOPROTECTOR PHOSPHONATES
EP1278526A2 (en) 2000-03-28 2003-01-29 Medicure International Inc. Treatment of cerebrovascular disease
ATE364595T1 (en) 2000-07-07 2007-07-15 Medicure Int Inc PYRIDOXINE AND PYRIDOXAL ANALOGS AS CARDIOVASCULAR THERAPEUTICS
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
WO2004084895A2 (en) * 2003-03-27 2004-10-07 Medicure, Inc. Modulation of cell death
WO2006050598A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
JP2008526783A (en) * 2005-01-05 2008-07-24 メディキュア・インターナショナル・インコーポレーテッド Compounds and methods for modulating triglyceride levels
FR3038227B1 (en) * 2015-06-30 2018-08-17 Assistance Publique - Hopitaux De Paris EFFERVESCENT FORMULATION BASED ON PYRIDOXAL-5-PHOSPHATE
WO2020003363A1 (en) * 2018-06-25 2020-01-02 学校法人近畿大学 Nutrition supplement or pharmaceutical composition for preventing deterioration in blood vessels due to the impact of ingesting nicotine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3373E (en) 1904-02-26 1904-10-27 Joseph Louis Felix Garrigou Process for treating emptying and organic waste, and overall apparatus for its implementation
FR6707M (en) * 1966-04-29 1969-02-17
GB1070120A (en) * 1966-05-06 1967-05-24 Tanabe Seiyaku Co Pyridoxine derivative and the preparation thereof
FR7238M (en) * 1968-03-27 1969-09-01
FR2035765A1 (en) 1969-03-06 1970-12-24 Inst Rech Scient Medicaments contg pyridoxine heparinates or - other vitamin b6 heparinates
JPS5347110B2 (en) * 1971-11-02 1978-12-19
FR2176509A2 (en) 1972-03-21 1973-11-02 Inst Rech Scient Pyridoxine p-chlorophenoxyisobutyrate prodn - giving very pure product from corresp acid and pyridoxine
JPS5018470A (en) * 1973-05-31 1975-02-26
FR2260330A1 (en) 1974-02-07 1975-09-05 Innothera Lab Sa Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index
CH607773A5 (en) 1974-12-24 1978-10-31 Steigerwald Arzneimittelwerk Process for the preparation of novel pyridoxine derivatives
DE2461742C2 (en) 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxine-5'-phosphoric acid ester derivatives and their preparation and pharmaceuticals containing these compounds
FR2349330A1 (en) * 1976-04-29 1977-11-25 Savini Emile Compsns. contg. pyridoxine and an antioxidant esp. tocopherol - used for treatment of hyperlipidaemia
JPS5347110A (en) * 1976-10-12 1978-04-27 Osaka Bosui Kensetsusha Kk Impermeable wall forming method

Also Published As

Publication number Publication date
ES2052609T3 (en) 1994-07-16
EP0282696A2 (en) 1988-09-21
DE3705549A1 (en) 1988-09-01
GR3006693T3 (en) 1993-06-30
KR950009094B1 (en) 1995-08-14
JPH07238020A (en) 1995-09-12
DE3875760D1 (en) 1992-12-17
HUT47850A (en) 1989-04-28
KR880009649A (en) 1988-10-04
CA1340246C (en) 1998-12-15
JPS63203621A (en) 1988-08-23
EG18335A (en) 1992-09-30
DK55888A (en) 1988-08-19
EP0282696A3 (en) 1989-06-14
EP0282696B1 (en) 1992-11-11
DK55888D0 (en) 1988-02-03
JPH0710777B2 (en) 1995-02-08
ATE82125T1 (en) 1992-11-15
JP2588686B2 (en) 1997-03-05

Similar Documents

Publication Publication Date Title
EG18335A (en) Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis
KR950009098B1 (en) Pharmaceutical composition for use in treating clot formation
AU2490297A (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
HU896498D0 (en) Process for preparation of low volatility salts
AU7316591A (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
GB8806737D0 (en) Therapeutic composition & method
DE69230526D1 (en) POLYAMINIC ACID DISPERSING AGENT
BG49719A3 (en) Method for preparing of variants chirudine and their use
DE3273611D1 (en) Infusion solutions for heart therapy
AU2005188A (en) Pharmaceutical composition for intranasal administration comprising gh-releasing hormone, a cholinergic agonist and in case a bile salt
GR900300043T1 (en) Use of the enzyme-cofactor nadph in the preparation of a pharmaceutical, pharmaceutical and preparation thereof
HK217196A (en) Diamine salts of clavulanic acid
AU639097B2 (en) Medicament for treating hyperlipidaemia and/or atherosclerosis
AU1463888A (en) Nitrification-inhibiting agent
GR3005222T3 (en)
AU3934689A (en) New furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
IL81549A0 (en) Pharmaceutical compositions containing glycerophosphoryl-o-serine or a salt thereof,certain such novel salts and their preparation
EP0286802A3 (en) Use of ofloxacin in treating or preventing locally periodontal disease
HU9200025D0 (en) Medical preparations for treating depression
ZA871140B (en) Synergistic chemical compositions for treating salmonellosis
GB2206338B (en) Fine filler dentifrice
DE3869772D1 (en)
AU6686490A (en) Pesticide composition
IT1174592B (en) Compsn. for treatment of diarrhoea